 | Standardize the Building Blocks Use validated, sequence-verified nucleases, guides, and donors to reduce run-to-run variability and simplify comparability as indications expand. |
 | Layer the Analytics Combine nanoparticle characterization, deep multiomics, and image-based phenotyping to connect edit efficiency with potency, safety, and mechanism of action. |
 | Consider Phase-Appropriate Manufacturing Select reagents and contract development and manufacturing organization partners that offer a clear path from research use only to current good manufacturing practices, enabling scale-up without resetting process or documentation. |
 | Design for Delivery Early Align nuclease, guide, and lipid nanoparticle choices with target cells and therapeutic modality from the start to avoid late-stage reformulation and revalidation. |
 | Build Data Flows Ready for Investigational New Drug Applications Centralize sequencing, imaging, mass spectrometry, and flow cytometry data into an audit-ready platform, so teams can assemble regulatory narratives at filing time rather than reconstruct them. |
To learn more, sign up to view the webinar From Design to Delivery: A Translational Framework for Non-Viral Gene Editing, or visit Danaher Life Sciences gene editing solutions.
